Editor's choice


Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors

Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is a clear association between increasing levels of LDL cholesterol (LDL-C) and incident cardiovascular risk.1 This has prompted efforts to develop a range of therapeutic strategies that lower LDL-C levels.

Cardiovascular Implications of Sphingomyelin Presence in Biological Membranes

Sphingolipids are one of the major categories of lipids and beyond their role as structural membrane components they have important functions as signalling molecules in a wide array of biological processes. They are composed of two key lipid building blocks – long-chain bases (usually sphingosine or 1,3-dihydroxy-2-amino-4-octadecene) and fatty acids – and use a glycerol-based backbone to which acyl chains are attached.1,2

PCSK9 inhibition could ameliorate cardiovascular disease by immune mechanisms

Barcelona, Spain – 28 Aug 2017: PCSK9 inhibition could ameliorate atherosclerosis and thus cardiovascular disease by immune mechanisms that are unrelated to lowering of low-density lipoprotein (LDL) cholesterol, according to research presented today at ESC Congress.1

T cells and dendritic cells are common in atherosclerotic plaques. Atherosclerosis is a chronic inflammatory process in which activation of these immune cells may play a major role in the development of cardiovascular disease.

Guest Editorial: Commentary on the Findings of the GLAGOV Randomized Clinical Trial

Atherosclerosis is the primary cause of coronary artery disease morbidity and mortality worldwide.1 Low-density lipoprotein cholesterol (LDL-C)- lowering therapies have already become one of the most important in the prevention of atherosclerosis complications.2 Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) and thus significantly reduces levels of LDL-C, and has been tested in a series of clinical trials on a wide range of lipid disorders.3,4